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Summary
Background A T-helper (Th) cell subset Th17 preferentially produces interleukin
(IL)-17 and plays a pivotal role in the pathogenesis of psoriasis. However, the
pathological roles of IL-17 cascades in generalized pustular psoriasis (GPP) and
psoriatic erythroderma (PsE) have not been well established.
Objectives To evaluate the efficacy and safety of brodalumab, a human
immunoglobulin G2 monoclonal antibody against human IL-17-receptor A (IL-
17RA), in Japanese patients with GPP and PsE.
Methods This was an open-label, multicentre, long-term phase III study in Japa-
nese patients with rare and severe types of psoriasis. Patients received bro-
dalumab 140 mg at day 1 and weeks 1 and 2, and then every 2 weeks until
week 52. The primary endpoint was the Clinical Global Impression of Improve-
ment (CGI). Safety evaluations included treatment-emergent adverse events (AEs)
and changes in laboratory parameters.
Results A total of 12 patients with GPP and 18 with PsE were enrolled. Ten
patients with GPP and 16 with PsE completed the study. At week 52 (last obser-
vation carried forward), CGI remission or improvement was achieved in 11
patients with GPP and 18 with PsE. The most commonly reported AE was
nasopharyngitis (333%). Five serious AEs occurred during the study. However,
none was considered treatment-related.
Conclusions Brodalumab significantly improved the symptoms of patients with GPP
and PsE throughout the 52 weeks, and demonstrated favourable safety profiles
without any new safety signals. Inhibition of IL-17RA-mediated signalling by
brodalumab is expected to be a promising new treatment option for patients
with GPP and PsE.
What’s already known about this topic?
• The pathological roles of interleukin (IL)-17 cascades in severe types of psoriasis
including generalized pustular psoriasis (GPP) and psoriatic erythroderma (PsE)
have not been well established.
What does this study add?
• Brodalumab significantly improved the symptoms of patients with GPP and PsE
throughout the 52 weeks and demonstrated favourable safety profiles without any
new safety signals.
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• Brodalumab is expected to be a promising new treatment option for patients with
GPP and PsE by blocking IL-17-receptor A-mediated signalling.
Psoriasis is a chronic inflammatory skin disease characterized
histologically by hyperproliferation and abnormal differentia-
tion of keratinocytes and inflammatory cell infiltration. Gener-
alized pustular psoriasis (GPP) is the most severe type,
producing sterile pustules over a wide area of the body and
occasionally causing fatal systemic symptoms. It is character-
ized by repeating recurrence or worsening.1 Psoriatic erythro-
derma (PsE) is another severe form characterized by diffuse
redness and scaling covering nearly the whole body, poten-
tially leading to fatal symptoms.
T-helper (Th) 17 cells preferentially produce interleukin
(IL)-17, and IL-17A, IL-17F, IL-17A/F heterodimer and IL-
17E (IL-25) share a common receptor subunit, IL-17 recep-
tor A (IL-17RA), for intracellular signalling. Excessive IL-17
signalling is thought to play an important role in the
pathogenesis of psoriasis.2 In patients with GPP and PsE,
increased Th17 cells and elevated IL-17 levels are also
reported.3–7
Brodalumab is a Chinese hamster ovary cell-derived human
immunoglobulin G2 monoclonal antibody against human IL-
17RA that blocks the biological activities of IL-17. Findings
from phase II and III studies of brodalumab in the U.S.A., Eur-
ope and other countries showed significant improvements in
plaque psoriasis and psoriatic arthritis.8–13 However, the effi-
cacy and safety of IL-17RA blockade in the severe forms of
psoriasis (GPP and PsE) have not been established. The aim of
this study is to validate the efficacy and safety of brodalumab
in Japanese patients with GPP or PsE.
Methods
Study design
This study was a phase III, open-label multicentre study in
patients with GPP or PsE. Patients received subcutaneous injec-
tions of brodalumab 140 mg at day 1, weeks 1 and 2, and
thereafter every 2 weeks until week 52. Patients were allowed
to increase the dose to 210 mg at week 4 and beyond if the
Pustular Symptom Score (PSS) in patients with GPP was rated
as moderate or severe (Table 1) and if patients with PsE did
not achieve ≥ 50% reduction of the Psoriasis Area and Severity
Index (PASI) scores. Patients who received an increased dose
of 210 mg were not allowed to return to 140 mg. This study
was conducted in accordance with the Declaration of Helsinki
and the Good Clinical Practice guidelines. The institutional
review boards at each study site approved the study protocol.
Each patient provided written informed consent before partici-
pating. The first patient provided written informed consent on
15 January 2013, and the last patient last visit was on 21 May
2014.
Patients
Patients at least 18 years of age were eligible for the study if
they met the diagnostic criteria provided in the therapeutic
guidelines for the treatment of GPP in Japan (Table 2)1 or had
a diagnosis of PsE with more than 80% body surface area
(BSA) involvement at baseline.14 Enrolment required negative
test results for hepatitis B virus surface antigen, hepatitis C
virus antibodies, human immunodeficiency virus antigen and
antibodies, human T-cell lymphotropic virus type-1 antibod-
ies, and tuberculosis. Patients were excluded if they had gut-
tate psoriasis or drug-induced PsE, or if they had experienced
serious infections in the 8 weeks prior to signing the
informed consent form, congestive heart failure (New York
Heart Association class II, III or IV), myocardial infarction or
unstable angina pectoris within the preceding year, or if they
had an active malignancy or a history of malignancy within
5 years prior to consent.
Patients were excluded if they had received treatment with
ustekinumab within 12 weeks, infliximab within 8 weeks,
Table 1 Pustular symptom score evaluation
Severity





A. Skin symptoms (total scores; 0–9)
Scores 3 2 1 0
Erythematous
area (BSA %)









≥ 50 ≥ 10, < 50 < 10 0
B. Systemic symptoms and laboratory findings (total scores; 0–8)
Scores 2 1 0













< 30 ≥ 30 to < 38 ≥ 38
BSA, body surface area (0–100); CRP, C-reactive protein.
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psoralen plus ultraviolet (UV) A light therapy within 4 weeks,
adalimumab or UVB phototherapy within 2 weeks, etanercept
or granulocytapheresis within 1 week, or if they had received
another anti-IL-17 antibody before starting the study. The use
of ciclosporin was not allowed during the study. The use of
methotrexate, vitamin A preparations, and/or oral steroids
was allowed provided the patient had been using such medi-
cation(s) since before starting the study. Dose reduction of
these drugs was allowed as well; however, dose increase after
dose reduction was limited to the level at the start of the
study.
Efficacy assessments
The primary endpoint of this trial was the Clinical Global
Impression of Improvement (CGI). CGI was evaluated by the
investigators on a four-point scale (remission, improved, no
change, worsened) based on changes from the baseline find-
ings of psoriasis.
Secondary endpoints included the percentage improvement
in PASI scores from baseline. In the patients with PsE, the pro-
portion of patients with a static Physician’s Global Assessment
(sPGA) of 0 or 1 and a change in BSA involvement were also
evaluated. The severity of patients with GPP was evaluated
according to the PSS provided in the 2010 therapeutic guideli-
nes for GPP treatment by the Japanese Research Team on
Intractable Skin Diseases, based on skin symptoms (erythema-
tous area, erythematous area with pustule, oedematous area)
and systemic symptoms/laboratory findings (fever, white
blood cell count, C-reactive protein, serum albumin)
(Table 1).1 Severity was evaluated at each visit, with the
total score (0–17) determined [0–6 (mild), 7–10 (moderate),
11–17 (severe)].
Explanatory endpoints included the Nail Psoriasis Severity
Index (NAPSI), the Psoriasis Scalp Severity Index (PSSI) and
patient-reported outcomes. NAPSI and PSSI evaluations were
performed only in patients who had symptoms at baseline.
Patient-reported outcomes included the Dermatology Life
Quality Index (DLQI),15 the Psoriasis Disability Index (PDI),16
and the 36-item Short Form Health Survey (SF-36).17 Photo-
graphic records of lesions were taken from patients who gave
informed consent.
Safety assessments
Safety evaluations included adverse events (AEs), serious AEs
(SAEs), and changes in laboratory parameters. The Common
Terminology Criteria for Adverse Events version 4.0 was used
to grade AE severity. Frequencies of all AEs that occurred or
worsened after the start of the study were analysed by both
preferred term and system organ class as described in the Japa-
nese version of the International Conference on Harmonisation
medical dictionary for regulatory activities, version 17.0.
Pharmacokinetics and antidrug antibody assays
Serum concentrations of brodalumab were measured at base-
line, and at weeks 2, 4, 8, 12, 24 and 48. Pharmacokinetic
parameters, including the time to peak concentration (tmax),
peak concentration (Cmax) and the area under the concentra-
tion–time curve over the dosing interval (AUC0–s) for weeks
8–10 were calculated with additional pharmacokinetic
sampling data from patients who had given consent. Serum
anti-brodalumab-binding antibody levels were measured at
baseline, and at weeks 4, 12, 24, 36 and 52 or discontinua-
tion. If the binding antibody was detected, neutralizing activ-
ity was also measured.
Data and statistical analysis
The CGI was summarized by the number and percentage of
patients for each scale. The number and percentage of patients
classified as ‘improved’ or ‘remission’ were also determined.
On secondary and explanatory endpoints, categorical data
were expressed in terms of frequency and percentage of




1. Systemic symptoms such as fever and general malaise
are present
2. Multiple, aseptic pustules are present in flushed skin
over the whole body or over a wide area. Occasionally,
several small pustules fuse together, forming a larger
confluent pustule
3. Neutrophilic subcorneal pustular dermatosis, which
is characterized by the Kogoj’s spongiform pustules,
is confirmed histopathologically
4. Recurrence of the above-listed clinical and histological
findings
The diagnosis of absolute GPP is made if all the above
criteria are met; the diagnosis of suspected GPP is made
if criteria 2 and 3 are met. In the case of new-onset GPP, the
following diseases can be excluded by the clinical course:
Exclusion criteria
1. As a general rule, the diagnosis of GPP should not be made
in patients who have an apparent history of previous psoriasis
vulgaris that has become transiently pustular due to
adrenocorticosteroid hormones or other drugs or due
to withdrawal of these drugs. However, its diagnosis
may be made at the discretion of a dermatologist if
he or she closely monitors the patient for a designated
period of time and finds that pustulation takes place
repeatedly and readily in the patient
2. The type classified as ‘circinate annular form’ is excluded
as it is generally associated with minimal systemic symptoms.
The diagnosis of GPP should be made only in patients in
whom the condition has clearly progressed to GPP
3. The diagnosis of GPP should not be made if the
diagnosis of subcorneal pustular dermatosis or pustular-type
drug eruption (including acute generalized exanthematous
pustulosis) is confirmed as a result of close monitoring for a
designated period of time
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patients, while continuous variables were summarized in
terms of summary statistics (number of patients, mean, stan-
dard deviation, minimum, median and maximum). Missing
values were not imputed and were analysed as observed. In
addition to observed case analysis, last observation carried for-
ward (LOCF) analysis was utilized for week 52. Given the
very small number of patients with GPP or PsE in Japan, the
target number of patients was set to be at least eight, with at
least four patients with each disease.
Results
Patient disposition and baseline characteristics
Thirty-two patients gave written informed consent. Twelve
patients with GPP and 18 patients with PsE were enrolled
(Fig. 1); two were excluded by the exclusion criteria. Twenty-
six patients completed the evaluation at week 52. Four patients
were discontinued: two patients with GPP because of AE and
investigators’ discretion owing to worsening symptoms, and
two patients with PsE because of AE and pregnancy. Dosages
for three patients with GPP and five patients with PsE were
increased to 210 mg according to the investigators’ decision.
Patient demographics and other baseline clinical characteristics
are shown in Table 3.
Efficacy
Efficacy results at week 12 and week 52 (LOCF) are shown in
Table 4. In patients with GPP, nine of 12 (750%) and 10 of
12 (833%) achieved a CGI classified as ‘improved’ or ‘remis-
sion’ at week 2 and at week 12, respectively. At week 52
(LOCF), 11 of 12 (917%) achieved ‘improved’ or ‘remission’
(Fig. 2a). In patients with PsE, 17 of 18 (944%) and 18 of
18 (100%) achieved a CGI classified as ‘improved’ or ‘remis-
sion’ at week 2 and at week 12, respectively. At week 52
(LOCF), 18 of 18 (100%) were classified as ‘improved’ or ‘re-
mission’ (Fig. 2b). Representative photographs of a patient
with GPP and one with PsE are shown in Figures 2c,d.
In patients with GPP, the PSS (0–17) was ‘mild’ (0–6) in
10 of 12 (833%) and ‘moderate’ (7–10) in two of 12
(167%) at baseline. After brodalumab treatment, four of 12
(333%) had a score of 1 at week 2. At week 12, three of 12
(250%) had a score of 0 and five of 12 (417%) had a score
of 1. At week 52 (LOCF), six of 12 (500%) had a score of 0,
five of 12 (417%) had a score of 1, and one of 12 (83%)
had a score of 5. Changes in PSS are shown in Figure 3a.
Changes in PASI scores over time are shown in Figure 3b.
Among the patients with PsE, the mean PASI score improve-
ment was 4803% at week 2 and 8506% at week 12. At week
52 (LOCF), the average PASI score improvement including
two discontinued cases was 9341%. Both PASI 75 and PASI
90 achievement rates at week 52 (LOCF) were 889%
(Table 4). PASI 100 response was 611% at week 52 (LOCF).
PASI 75, PASI 90 and PASI 100 achievement rates for patients
with GPP are shown in Figure 4a. The percentage of patients
with PsE with sPGA of 0 or 1 increased over time after bro-
dalumab treatment, with five of 18 (278%) at week 2, 12 of
18 (667%) at week 12 and 16 of 18 (889%) at week 52
(LOCF).
Other efficacy assessment results are shown in Table 4.
Mean BSA improvement was 7270% at week 12 and 8461%
at week 52 (LOCF) in PsE. At week 52 (LOCF), the change in
DLQI score was 55 and 61 in GPP and PsE, respectively.
At week 52 (LOCF), 667% of patients with GPP and 889%
of patients with PsE reported a DLQI total score of ‘0 or 1’.
Two patients with GPP and five with PsE had been using
vitamin A preparations since before starting the study. Of
these patients, one patient with GPP and four with PsE discon-
tinued the treatment with vitamin A preparations after bro-
dalumab administration.
Safety and adverse events
Incidences of AEs are summarized in Table 5. Of the 30
patients, AEs occurred in 11 of 12 (917%) patients with GPP
and in 17 of 18 (944%) of patients with PsE. Among patients
with GPP and PsE, the most common AE was nasopharyngitis
in four of 12 (333%) and six of 18 (333%) of patients with
GPP and PsE, respectively. There were no AEs leading to
death.
Serious adverse events occurred in five patients: three of 12
patients with GPP (lumbar vertebral fracture, exacerbation of
pustular psoriasis and hepatocellular carcinoma) and two of
Enrolled n =12
140 mg; n = 12
Discontinued n = 2
Investigators’ discretion due to 
worsened GPP (n = 1)
Adverse event (n = 1)
GPP
Completed n = 7 Completed n = 3
Increased to 210 mg; n = 3
Enrolled n = 18
140 mg; n = 18
Discontinued n = 2
Pregnancy (n = 1)
Adverse event (n = 1)
PsE
Completed n = 11 Completed n = 5
Increased to 210 mg; n = 5
Fig 1. Patient disposition chart. GPP,
generalized pustular psoriasis; PsE, psoriatic
erythroderma
© 2016 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2017) 176, pp741–751
744 Brodalumab in patients with GPP and PsE, K. Yamasaki et al.
18 patients with PsE (ectopic pregnancy and prostate cancer),
but only hepatocellular carcinoma and prostate cancer led to
study discontinuation. The ‘prostate cancer’ was noted on day
148 in a 75-year-old male patient with PsE. The investigator
judged that the event was ‘not related’ to brodalumab and
was likely developed naturally given the patient’s age and diet-
ary style. The ‘hepatocellular carcinoma’ was noted on day
261 in a 70-year-old female patient with GPP. The investiga-
tor judged that the event was ‘not related’ to brodalumab
given the history of hepatitis B, long-term treatment with con-
comitant drugs and the patient’s age. The ‘lumbar vertebral
fracture’ occurred on day 23 in a 39-year-old male patient
with GPP who used topical/oral steroids for the treatment of
psoriasis and had osteoporosis as a concomitant disease. The
‘exacerbation of pustular psoriasis’ event of a 36-year-old male
patient on day 225 stabilized after the brodalumab dose
was increased to 210 mg on day 225 and resolved on day
242. The ‘ectopic pregnancy’ was noted on day 132 in a
Table 3 Baseline demographics and clinical characteristics
GPP (N = 12) PsE (N = 18) All (N = 30)
Age (years), mean ( SD) 431 ( 168) 508 ( 122) 477 ( 145)
Sex (male), n (%) 3 (250) 14 (778) 17 (567)
Body weight (kg),
mean ( SD)
5857 ( 1669) 6575 ( 1216) 6288 ( 1433)
BMI (kg m2), mean ( SD) 2254 ( 546) 2433 ( 489) 2362 ( 511)
Duration of disease (years),
mean ( SD)
656 ( 720) 637 ( 1012) NA
Prior systemic therapy –
nonbiologics, n (%)
10 (833) 14 (778) 24 (800)
Ciclosporin, n (%) 10 (833) 10 (556) 20 (667)
Retinoid, n (%) 8 (667) 9 (500) 17 (567)
Steroid, n (%) 6 (500) 3 (167) 9 (300)
Methotrexate, n (%) 1 (83) 4 (222) 5 (167)
Other, n (%) 0 2 (111) 2 (67)
Phototherapy, n (%) 8 (667) 17 (944) 25 (833)
UVB treatment, n (%) 6 (500) 12 (667) 18 (600)
PUVA treatment, n (%) 4 (333) 10 (556) 14 (467)
Prior biologics, n (%) 6 (500) 2 (111) 8 (267)
Adalimumab, n (%) 2 (167) 2 (111) 4 (133)
Infliximab, n (%) 6 (500) 1 (56) 7 (233)
Ustekinumab, n (%) 2 (167) 0 2 (67)
Plaque psoriasis in the past or
complication, n (%)
7 (583) NA NA
PASI score, mean ( SD) 1501 ( 1208) 3610 ( 1311) 2766 ( 1632)
PSS, mean ( SD) 44 ( 24) NA NA
sPGA
0 (clear), n (%) NA 0 NA
1 (minimal), n (%) NA 1 (56) NA
2 (mild), n (%) NA 5 (278) NA
3 (moderate), n (%) NA 3 (167) NA
4 (severe), n (%) NA 3 (167) NA
5 (very severe), n (%) NA 6 (333) NA
BSA involvement (%), mean ( SD) NA 8794 ( 460) NA
NAPSI, mean score ( SD), n 108 ( 79), 4 62 ( 33), 13 72 ( 49), 17
PSSI, mean score ( SD), n 167 ( 130), 9 354 ( 182), 18 291 ( 187), 27
DLQI, mean score ( SD) 79 ( 55) 71 ( 68) 74 ( 62)
PDI, mean score ( SD) 112 ( 88) 142 ( 84) 130 ( 85)
SF-36
Physical component,
mean score ( SD)
4516 ( 1462) 4899 ( 1203) 4746 ( 1302)
Mental component,
mean score ( SD)
4860 ( 996) 4794 ( 1119) 4820 ( 1054)
BSA, Body surface area (0–100); BMI, body mass index; DLQI, Dermatology Life Quality Index (0–30); GPP, generalized pustular psoriasis;
NA, not assessed; NAPSI, Nail Psoriasis Severity Index (0–32); PASI, Psoriasis Area and Severity Index (0–72); PDI, Psoriasis Disability Index
(0–45); PSS, Pustular Symptom Score (0–17); PsE, psoriatic erythroderma; PSSI, Psoriasis Scalp Severity Index (0–72); PUVA, psoralen plus
ultraviolet A light therapy; SF-36, 36-item Short Form Health Survey from the Medical Outcomes Study (0–100); sPGA, static Physician’s
Global Assessment (0–5); UVB, narrowband ultraviolet B therapy.
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35-year-old female patient with PsE. This event was judged
initially to be pregnancy and led to study discontinuation. After
that, the diagnosis was changed to ‘ectopic pregnancy’. None of
the SAEs was considered treatment- or protocol-related.
All AEs related to infection were grade 1 or 2 in severity.
Grade 3 ‘neutrophil count decreased’ occurred in one of 12
(83%) patients with GPP, of which a causal relationship to
brodalumab was judged ‘not related’ by the investigator
because the event was accompanied by upper respiratory
inflammation. The neutrophil count was 4913 lL1 before
the treatment (day 1) and decreased to 818 lL1 on week
12. With the level decreased to < 1000 lL1, brodalumab
was not administered on week 12 as per protocol require-
ment. Thereafter, the level returned to 7112 lL1 on week
14. Brodalumab was resumed on week 14 and continued up
to week 52. Grade 2 ‘oesophageal candidiasis’ occurred in one
of 18 (56%) patients with PsE and grade 2 ‘oral candidiasis’
occurred in one of 12 (83%) patients with GPP. These
patients used the concomitant anti-candida medication and
completed the study. ‘Injection site irritation’, ‘injection site
swelling’ and ‘injection site macule’, were each observed in
one of 12 patients with GPP (83%). All of these events were
grade 1. No suicide-related events occurred. Of the 30 patients,
one (33%) tested positive for anti-brodalumab-binding
antibodies; however, no anti-brodalumab neutralizing anti-
bodies were detected.
Pharmacokinetics
Trough serum concentrations of brodalumab reached a steady
state by week 8 and remained nearly constant. The serum con-
centration–time profiles for weeks 8–10 after multiple 140 mg
subcutaneous administrations showed no marked difference
between patients with GPP and those with PsE: Cmax
(mean  SD) was 101  91 and 118  86 lg mL1,
AUC0–s (mean  SD) was 920  899 and 125  108 lg
d mL1, and tmax (median) after a dose of 140 mg at week
8 was 297 and 199 days in GPP (n = 4) and PsE (n = 4),
respectively.
Discussion
Generalized pustular psoriasis affects approximately 2000
patients in Japan.18 Because GPP occasionally causes extensive
sterile pustules and fatal systemic symptoms, GPP has been
designated as a target disease by the Practical Research Project
for Rare/Intractable Diseases (Research Team on Rare and
Intractable Skin Diseases), and all patients with GPP in Japan
Baseline PASI score: 42·9 Week 52 PASI score: 0
Pustular symptom score: 10 Pustular symptom score: 1
Baseline PASI score: 58·5 Week 12 PASI score: 0
Percentages of patients with a CGI assessment of 'remission',



































































Fig 2. Percentages of patients with a CGI assessment of ‘remission’, ‘improved’, ‘no change’ or ‘worsened’ at each evaluation time point
(symptom change from baseline) for patients with GPP (a) and patients with PsE (b). LOCF analysis was used to impute missing data for week
52. (c) Clinical response to brodalumab 210 mg after 140 mg in a patient with GPP (at baseline and after 52 weeks). (d) Clinical response to
brodalumab 140 mg in a patient with PsE (at baseline and after 12 weeks). CGI, Clinical Global Impression of Improvement; GPP, generalized
pustular psoriasis; LOCF, last observation carried forward; PsE, psoriatic erythroderma.
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are registered.19 PsE causes erythema and scaling over a large
area of the body, leading to fatal systemic symptoms including
depletion of serum proteins. GPP and PsE are rare diseases
with each estimated to affect 1% of all patients with psoriasis.
Patients with GPP are currently treated with oral medications
such as retinoids and ciclosporin or systemic therapies such as
anti-tumour necrosis factor (TNF)-a agents, according to the
Japanese Guidelines for GPP.1 Furthermore, only infliximab
has been approved for GPP and PsE in Japan so far. Therefore,
there is an increasing need for a new treatment option for
patients with these two types of severe and treatment-refrac-
tory psoriasis.
The IL-17RA-mediated IL-17A signal transduction plays a
significant role in plaque psoriasis. Patients with GPP have
increased levels of IL-17 and an increased number of IL-17-
producing cells in both blood and lesional skin.3–6 In addi-
tion, the skin lesions of PsE show Th17 cell accumulations
similar to those of plaque psoriasis.7 Because brodalumab
binds selectively to human IL-17RA and inhibits IL-17RA-
mediated signalling, the investigators expected that bro-
dalumab would improve clinical symptoms in GPP and PsE.
In patients with PsE, brodalumab significantly improved the
symptoms from early visits, as shown in Figures 3 and 4. As
observed in other clinical trials for plaque psoriasis,8–10,12,13
brodalumab demonstrated robust efficacy against PsE and sus-
tained symptom improvement up to week 52. We set the dose
increase criteria in patients with PsE based on the PASI score,
not on the primary endpoint CGI, in order to assess disease exac-
erbation objectively. Five patients with PsE met the dose increase
criteria; in these patients, the dose was increased to 210 mg,
and these patients improved rapidly at this higher dose.
We primarily evaluated efficacy for patients with GPP by
CGI and used PASI as reference information because the per-
centage improvement in PASI scores from baseline was defined
as secondary endpoints in other clinical trials for patients with
GPP in Japan.14,20 Although patients with GPP often experi-
ence repeated cycles of systemic and pustular symptoms over
the course of a year, brodalumab prevented these symptoms
from worsening throughout the study period. The PSS, but
not the CGI and PASI scores, was set for the dose increase cri-
teria in patients with GPP because the PSS evaluates general
symptoms as well as skin symptoms objectively and because
the PASI score is not an optimal instrument for GPP, which
often has general symptoms. One patient with GPP with CGI
classified as ‘worsened’ withdrew from the study on day 201.
The patient was a 45-year-old female with type 2 diabetes,
hyperlipidaemia, and 955 kg body weight at baseline. The
patient did not meet the dose increase criteria because her PSS
was 5 on day 201 and she was switched to another biologic
therapy after week 28 without increasing to 210 mg. The
other three patients with GPP who met the dose increase crite-





















































Fig 3. (a) Pustular symptom score over time
in patients with generalized pustular psoriasis
(mean  SD). (b) Psoriasis Area and Severity
Index (PASI) score over time in patients with
psoriatic erythroderma (mean  SD).
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Given the data observed so far, an initial dose of 140 mg
might be insufficient for some patients with either of these
diseases.
Rapid symptom improvements were observed across all end-
points, with sustained efficacy throughout the study. A DLQI
total score of ‘0 or 1’ is important to augment a patient’s satis-
faction with treatment.21,22 In this study, 667% of patients
with GPP and 889% of patients with PsE achieved the DLQI
total score of ‘0 or 1’ at week 52 (LOCF), which demonstrates
that brodalumab improved the quality of life of these patients.
The severity of most AEs was either grade 1 or 2. No par-
ticular events raised any concerns of delayed-type AEs, con-
firming brodalumab’s safety and tolerability up to week 52.
As reported in other clinical trials,8–13 the incidence rate of
anti-brodalumab antibody development in our trial was very
low, and the efficacy was maintained even over long-term
administration. Consequently, patient discontinuation due to
insufficient efficacy was low. Therefore, brodalumab appears
suitable for long-term use in patients with GPP and PsE.
Six patients with GPP and two patients with PsE reported
prior treatment with a biologic. In this subgroup, the CGI was
assessed as ‘improved’ or ‘remission’ in five (833%) patients
with GPP and two (100%) patients with PsE at week 52
(LOCF). With a pharmacological action different from that of
anti-TNF-a agents, brodalumab may be effective for patients
with GPP and those with PsE with a prior history of biologics.
Among patients with GPP, four had new-onset GPP, seven
had GPP preceded by plaque psoriasis and for one patient this





























































Fig 4. (a) PASI 75, PASI 90 and PASI 100
responses over time for patients with
generalized pustular psoriasis (GPP). (b) PASI
75, PASI 90 and PASI 100 responses over
time for patients with psoriatic erythroderma
(PsE). PASI, Psoriasis Area and Severity Index







Adverse events, n (%)
All 11 (917) 17 (944) 28 (933)
Death 0 0 0
Serious 3 (250) 2 (111) 5 (167)
Common adverse eventsa
Nasopharyngitis 4 (333) 6 (333) 10 (333)
Diarrhoea 2 (167) 1 (56) 3 (100)
Folliculitis 2 (167) 1 (56) 3 (100)
Skin papilloma 2 (167) 1 (56) 3 (100)
Dry skin 2 (167) 1 (56) 3 (100)
Periarthritis 1 (83) 2 (111) 3 (100)
Dental caries 0 2 (111) 2 (67)




1 (83) 0 1 (33)
Candidiasisb 1 (83) 1 (56) 2 (67)
Injection site
reactionsc
3 (250) 0 3 (100)
GPP, generalized pustular psoriasis; PsE, psoriatic erythroderma;
N, number of patients in the safety analysis set; n, number of
patients reporting at least one occurrence of an adverse event.
aCommon adverse events were observed in at least two patients
in either the GPP or PsE patient group. bCandidiasis includes ‘oe-
sophageal candidiasis’ and ‘oral candidiasis’. cInjection site reac-
tions include ‘injection site irritation’, ‘injection site swelling’
and ‘injection site macule’.
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that new-onset GPP not preceding plaque psoriasis is attributa-
ble to the functional loss or genetic mutation of IL-36 recep-
tor antagonists.23,24 However, because of higher IL-17 levels
in patients with GPP,3–6 brodalumab showed efficacy for both
types of GPP.
Results from this study confirm that brodalumab can
improve patient symptoms not long after treatment is initiated.
Despite this trial’s open-label status and small sample size,
these data on rapid onset of action producing an excellent clin-
ical efficacy revealed that Th17 and IL-17 play important and
central roles in the pathogenesis of GPP and PsE. Consequently,
IL-17RA blocking will be a promising therapeutic target in
patients with GPP and PsE. The safety profile and low expres-
sion of anti-brodalumab antibody led us to conclude that bro-
dalumab is suitable for long-term use. Although the follow-up
period is limited to 52 weeks and longer observation is
required for these chronic diseases, the clinical efficacy and
safety of brodalumab represent significant values as a new first-
line therapeutic option for patients with GPP and PsE.
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